secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVADEL PHARMACEUTICALS PLC (—)
CIK:        0001012477
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047848
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avadel appoints Susan Rodriguez as COO; base salary $510K, 300K options
-----------------------------------------------------------------------

- Susan Rodriguez appointed as COO effective May 13, 2025; role is newly created.
- Base salary $510K, bonus potential 45% of salary, stock options for 300,000 shares vesting over 4 years.
- Previously served as Chief Commercial Officer at Ardelyx and CEO at Tolmar Pharmaceuticals.
- Appointment comes during LUMRYZ launch for narcolepsy; potential label expansion to idiopathic hypersomnia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1012477/000110465925047848/0001104659-25-047848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1012477/000110465925047848/tm2514853d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer